Robert Wesolowski

4.7k total citations
176 papers, 2.7k citations indexed

About

Robert Wesolowski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Robert Wesolowski has authored 176 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 59 papers in Pulmonary and Respiratory Medicine and 36 papers in Cancer Research. Recurrent topics in Robert Wesolowski's work include Advanced Breast Cancer Therapies (33 papers), Cancer Treatment and Pharmacology (31 papers) and HER2/EGFR in Cancer Research (28 papers). Robert Wesolowski is often cited by papers focused on Advanced Breast Cancer Therapies (33 papers), Cancer Treatment and Pharmacology (31 papers) and HER2/EGFR in Cancer Research (28 papers). Robert Wesolowski collaborates with scholars based in United States, United Kingdom and Switzerland. Robert Wesolowski's co-authors include William E. Carson, Joseph Markowitz, Bhuvaneswari Ramaswamy, Maryam B. Lustberg, Taylor Brooks, Richard Kim, Chan Lee, Tracey L. Papenfuss, Rachel M. Layman and Mathew Cherian and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Robert Wesolowski

165 papers receiving 2.6k citations

Peers

Countries citing papers authored by Robert Wesolowski

Since Specialization

Citations

This map shows the geographic impact of Robert Wesolowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Wesolowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Wesolowski more than expected).

Fields of papers citing papers by Robert Wesolowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Wesolowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Wesolowski. The network helps show where Robert Wesolowski may publish in the future.

Co-authorship network of co-authors of Robert Wesolowski

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Wesolowski. A scholar is included among the top collaborators of Robert Wesolowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Wesolowski. Robert Wesolowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA17 Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1 2025 ·Annals of Oncology ·(unknown), (unknown), G. Curigliano, (unknown), Massimo Cristofanilli, S-B. Kim, (unknown), Jorge Nadal, (unknown), George Emile, Robert Wesolowski, Miguel Martín, (unknown), Sarah C. Mutka, Sayaka Suzuki, (unknown), Igor Gorbatchevsky, (unknown)	1
2	Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer 2024 ·npj Breast Cancer ·(unknown), (unknown), Brett R. Loman, (unknown), Sagar Sardesai, Nicole Williams, Margaret E. Gatti‐Mays, Daniel G. Stover, Preeti Sudheendra, Robert Wesolowski, Rebecca Andridge, Michael T. Bailey, Leah M. Pyter	2
3	Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) 2024 ·Cancer Research ·(unknown), Fabrice André, Massimo Cristofanilli, Giuseppe Curigliano, (unknown), Hyo S. Han, Miguel Martín, Barbara Pistilli, Hope S. Rugo, Robert Wesolowski, Igor Gorbatchevsky, Sibylle Loibl	1
4	An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer 2024 ·Cancer Control ·Dionisia Quiroga, Robert Wesolowski, (unknown), (unknown), Brooke Benner, Emily Schwarz, (unknown), Courtney Johnson, Andrew Stiff, (unknown), Erin Macrae, Maryam B. Lustberg, Ewa Mrózek, Bhuvaneswari Ramaswamy, William E. Carson	3
5	Identifying Key Genes Involved in Axillary Lymph Node Metastasis in Breast Cancer Using Advanced RNA-Seq Analysis: A Methodological Approach with GLMQL and MAS 2024 ·International Journal of Molecular Sciences ·(unknown), Robert Wesolowski, Metin N. Gürcan	6
6	A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas 2024 ·Clinical Cancer Research ·Olivier Rixe, John L. Villano, Robert Wesolowski, Anne M. Noonan, Vinay K. Puduvalli, Trisha M. Wise‐Draper, Richard Curry, Emrullah Yilmaz, (unknown), Besim Öğretmen, (unknown), (unknown)	1
7	The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer 2023 ·Oncology and Therapy ·(unknown), Daniel A. Goldstein, (unknown), Dionisia Quiroga, Mahmoud Kassem, Michael Grimm, (unknown), Craig Vargo, Michael Berger, Preeti Sudheendra, Ashley Pariser, Margaret E. Gatti‐Mays, Nicole Williams, Daniel G. Stover, Sagar Sardesai, Robert Wesolowski, Bhuvaneswari Ramaswamy, Gary Tozbikian, Patrick Schnell, Mathew Cherian	1
8	Inflamed but not impulsive: Acute inflammatory cytokine response does not impact prepotent response inhibition 2023 ·Journal of Affective Disorders ·Annelise A. Madison, Rebecca Andridge, Megan E. Renna, John F. Sheridan, Maryam B. Lustberg, Bhuvaneswari Ramaswamy, Robert Wesolowski, Nicole Williams, Sagar Sardesai, Anne M. Noonan, Raquel E. Reinbolt, Mathew Cherian, William B. Malarkey, Janice K. Kiecolt‐Glaser	3
9	Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial 2023 ·PubMed Central ·Megan E. Renna, Annelise A. Madison, Juan Peng, M. Rosie Shrout, Maryam B. Lustberg, Bhuvaneswari Ramaswamy, Robert Wesolowski, Jeffrey VanDeusen, Nicole Williams, Sagar Sardesai, Anne M. Noonan, Raquel E. Reinbolt, (unknown), Mathew Cherian, (unknown), Rebecca Andridge, Janice K. Kiecolt‐Glaser	1
10	Conflicts hurt: social stress predicts elevated pain and sadness after mild inflammatory increases 2023 ·Pain ·Annelise A. Madison, Megan E. Renna, Rebecca Andridge, Juan Peng, M. Rosie Shrout, John F. Sheridan, Maryam B. Lustberg, Bhuvaneswari Ramaswamy, Robert Wesolowski, Nicole Williams, Anne M. Noonan, Raquel E. Reinbolt, Daniel G. Stover, Mathew Cherian, William B. Malarkey, Janice K. Kiecolt‐Glaser	5
11	204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients 2023 ·ESMO Open ·Hope S. Rugo, Robert Wesolowski, Erica Stringer-Reasor, Hyo S. Han, Jennifer M. Specht, (unknown), Peter Kabos, Ulka N. Vaishampayan, Seth A. Wander, Janice Lu, Keerthi Gogineni, Alexander I. Spira, Anne F. Schott, Maysa Abu‐Khalaf, Sarah C. Mutka, Samuel Suzuki, Igor Gorbatchevsky, Rachel M. Layman	1
12	Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors 2023 ·British Journal of Cancer ·Apostolia M. Tsimberidou, Claire F. Verschraegen, Robert Wesolowski, Chi‐Sheng Shia, (unknown), Tillman Pearce	5
13	Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase 2023 ·Molecular Cancer Research ·(unknown), Carter Allen, (unknown), (unknown), Dionisia Quiroga, Emily Schwarz, Richard C. Wu, (unknown), (unknown), (unknown), Andrew Stiff, (unknown), Bradley W. Blaser, Matthew Old, Robert Wesolowski, Gang Xin, Kari Kendra, Dongjun Chung, William E. Carson	4
14	Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center 2023 ·Modern Pathology ·Yan Hu, Dan Jones, Weiqiang Zhao, Gary Tozbikian, Robert Wesolowski, Anil V. Parwani, Zaibo Li	11
15	Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens 2022 ·Expert Review of Anticancer Therapy ·(unknown), Dionisia Quiroga, Preeti Sudheendra, Robert Wesolowski	4
16	Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer 2021 ·Journal of Clinical Oncology ·Aditya Bardia, Virginia Kaklamani, Sharon Wilks, Amy Weise, Donald Richards, Wael A. Harb, Cynthia R. Osborne, Robert Wesolowski, Meghan Karuturi, Paul Conkling, Rebecca G. Bagley, Yamei Wang, Maureen G. Conlan, Peter Kabos	67
17	Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development 2020 ·SHILAP Revista de lepidopterología ·Brooke Benner, (unknown), Dionisia Quiroga, (unknown), Mahmoud Kassem, (unknown), (unknown), Sagar Sardesai, Robert Wesolowski	4
18	<p>Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development</p> 2020 ·Drug Design Development and Therapy ·Brooke Benner, (unknown), Dionisia Quiroga, Thomas E Schultz, Mahmoud Kassem, William E. Carson, Mathew Cherian, Sagar Sardesai, Robert Wesolowski	121
19	Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience 2019 ·Journal of Oncology Pharmacy Practice ·(unknown), (unknown), Michael Berger, Craig Vargo, (unknown), Junan Li, Bhuvaneswari Ramaswamy, Raquel E. Reinbolt, Sagar Sardesai, Robert Wesolowski, Nicole Williams, Maryam B. Lustberg	4
20	Tumor Infiltrating Lymphocytes – The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer 2014 ·Journal of Carcinogenesis & Mutagenesis ·Robert Wesolowski, William E. Carson	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact